- Liminal BioSciences ( NASDAQ: LMNL ) said Thursday it discontinued development of fezagepras .
- The decision is based on results from the phase 1a single ascending dose clinical trial, which showed that fezagepras was significantly inferior to sodium phenylbutyrate as a nitrogen scavenger.
- The clinical trial, which began in May, was designed as a head-to-head comparison with sodium phenylbutyrate to evaluate whether fezagepras was worth developing.
- The decision to stop fezagepras' development was not based on safety concerns.
For further details see:
Liminal BioSciences discontinues fezagepras development